An Ongoing Phase 1 Study of ABT-263; Pharmacokineties, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

被引：0
|
作者：
Roberts, Andrew W. [1 ]
Brown, Jennifer [2 ]
Seymour, John F. [3 ]
Wierda, William G. [4 ]
Kipps, Thomas J. [5 ]
Xiong, Hao [6 ]
Chiu, Yi-Lin [6 ]
Busman, Todd [6 ]
Knight, Raymond A. [6 ]
Enschede, Sari [6 ]
Krivoshik, Andrew [6 ]
Humerickhouse, Rod [6 ]
机构：
[1] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haem, Parkville, Vic 3050, Australia
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Australia
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] CLL Res Consortium, Moores UCSD Canc Ctr, La Jolla, CA USA
[6] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1089 / 1090
页数：2
相关论文
共 50 条
  • [21] A phase II study of dasatinib in relapsed and-refractory chronic lymphocytic leukemia (CLL/SLL)
    Amrein, Philip C.
    Attar, Eyal C.
    Takvorian, Tak
    Hochberg, Ephraim P.
    Ballen, Karen
    Zabrieh, David
    Brown, Jennifer R.
    BLOOD, 2007, 110 (11) : 920A - 920A
  • [22] Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients
    Ahmed, Tamer
    Hayslip, John
    Leggas, Markos
    CANCER RESEARCH, 2012, 72
  • [23] Dasatinib Has Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL/SLL), a Phase II Trial
    Amrein, Philip C.
    Attar, Eyal
    Takvorian, Tak
    Hochberg, Ephraim
    Ballen, Karen K.
    Leahy, Kathleen M.
    Neuberg, Donna
    Brown, Jennifer R.
    BLOOD, 2008, 112 (11) : 1084 - 1084
  • [24] Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    McKay, John
    Al-Juhaishi, Taha
    Lai Guanhua
    Kmieciak, Maciej
    Sabo, Roy
    Sindel, Ariel
    Yazbeck, Victor
    BLOOD, 2019, 134
  • [25] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
    Wendtner, Clemens
    Hillmen, Peter
    Mahadevan, Daruka
    Stilgenbauer, Stephan
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David Duane
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    de Parseval, Laure Moutouh
    Chanan-Khan, Asher A.
    BLOOD, 2010, 116 (21) : 591 - 592
  • [26] A phase 1 study of ABT-263 in patients with relapsed small cell lung cancer (SCLC) and other solid tumors
    Gandhi, Leena
    Camidge, David R.
    de Oliveira, Moacyr R.
    Bonomi, Philip D.
    Gandara, David
    Chiu Yi-Lin
    Xiong, Hao
    Enschede, Sari H.
    Krivoshik, Andrew P.
    Rudin, Charles M.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S394 - S394
  • [27] Ongoing phase 1 study of a novel PARP inhibitor, ABT-888 in combination with temozolamide; Pharmacokinetics, safety and anti-tumor activity
    Molina, Julian
    Erlichman, Charles
    Northfelt, Donald
    Lensing, Janeth
    Giranda, Vincent
    CANCER RESEARCH, 2009, 69
  • [28] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S282 - S283
  • [29] A phase I/II study of the SYK inhibitor entospletinib in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
    Kittai, Adam
    Hashiguchi, Taylor
    Thurlow, Bria
    Gokcora, Basak
    Stadnik, Andrzej
    MacKinnon, Renee
    Stephen, Monette
    Moore, Lacey
    Persky, Daniel
    Park, Byung
    Spurgeon, Stephen
    Danilov, Alexey
    LEUKEMIA & LYMPHOMA, 2020, 61 : 76 - 77
  • [30] Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).
    Rogers, Kerry Anne
    Thompson, Philip A.
    Allan, John Nathan
    Coleman, Morton
    Sharman, Jeff Porter
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng Seok
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345